Regeneron Advances REGN9533 Blood Clot Treatment Through Phase 1 While Terminating Heart Failure Program
Key Insights
Regeneron Pharmaceuticals completed Phase 1 testing of REGN9533, a monoclonal antibody targeting Factor XII (search) for blood clot (search) prevention, marking progress in next-generation anticoagulation therapy.
The company terminated its Phase 2 heart failure (search) trial for REGN5381, an NPR1 (search) monoclonal antibody agonist, removing a potential cardiovascular pipeline asset.
REGN9533's completion in healthy volunteers positions the drug for advancement to patient studies, potentially offering a cleaner safety profile compared to existing oral anticoagulants.
Regeneron Pharmaceuticals has achieved a key milestone in its blood clot (search) prevention program while simultaneously closing a heart failure (search) development effort, highlighting the company's strategic focus in cardiovascular medicine. The biotech giant completed Phase 1 testing of REGN9533, an experimental monoclonal antibody targeting Factor XII (search), while terminating its Phase 2 trial of REGN5381 for heart failure patients.
REGN9533 Advances in Anticoagulation Market
The completed Phase 1 study of REGN9533 represents Regeneron's entry into next-generation blood clot (search) treatments, a market dominated by established players like Bristol Myers Squibb (search) and Pfizer. The trial, officially titled "A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN9533, a Monoclonal Antibody Against Factor XII (search), in Healthy Adults," tested the drug's safety profile in healthy volunteers.
REGN9533 works by blocking Factor XII (search), a protein involved in blood clot (search) formation. The study used a parallel-group design with participants randomly assigned to receive either REGN9533 or placebo at escalating dose levels. The double-blind approach ensured that participants, doctors, study staff, and outcome assessors remained unaware of treatment assignments to minimize bias.
The trial was first submitted in late October 2024 and achieved completed status by February 4, 2026, indicating that initial dosing and follow-up phases have concluded successfully. This progression positions the program for potential advancement into patient-focused Phase 2 studies, pending favorable safety data.
Heart Failure Program Discontinued
In contrast, Regeneron terminated its Phase 2 heart failure (search) trial for REGN5381, an NPR1 (search) monoclonal antibody agonist designed as a one-time intravenous infusion. The study, which began in January 2024, aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of a single dose in patients with chronic heart failure with reduced ejection fraction.
The terminated trial was testing whether REGN5381 could be safely added to standard care for chronic heart failure (search) patients. The study used a randomized, double-blind, placebo-controlled design with patients receiving either REGN5381 at different dose levels or placebo infusion. The termination, updated on January 13, 2026, indicates that active dosing and follow-up are no longer ongoing under this protocol.
Strategic Implications for Pipeline Development
The completion of REGN9533's Phase 1 study adds another potential asset to Regeneron's cardiovascular pipeline, which could diversify revenue streams beyond the company's established eye, inflammatory, and oncology franchises. Factor XII (search) inhibition represents an emerging class that could potentially offer a cleaner safety profile by avoiding excess bleeding complications associated with current oral anticoagulants.
The termination of the REGN5381 heart failure (search) program removes one potential near- to medium-term driver from Regeneron's cardiovascular pipeline. This decision reflects the high-risk nature of heart failure drug development, an area where companies like Novartis and AstraZeneca already compete with proven therapies.
For investors, these pipeline updates represent routine drug development decisions rather than thesis-changing events. The REGN9533 advancement reinforces Regeneron's commitment to long-duration, high-value platforms, while the heart failure (search) program termination likely reflects strategic resource allocation rather than a broader pullback from cardiovascular research and development.